Metformin suppresses NFE2L1 pathway activation to inhibit gap junction beta protein expression in NSCLC

ConclusionThis emphasizes the potential of targeting GJBs as a viable treatment approach for NSCLC patients receiving metformin.

Source: Cancer Medicine - April 2, 2024 Category: Cancer & Oncology Authors: Shuo Yu, Hui Ren, Tingting Liu, Xiaoyan Han, Hui Guo, Qian Ning, Yang Li, Hong Zhou, Mingwei Chen, Tinghua Hu Tags: RESEARCH ARTICLE Source Type: research